Riverwater Partners LLC Trims Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Riverwater Partners LLC reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,776 shares of the medical instruments supplier’s stock after selling 925 shares during the period. LeMaitre Vascular accounts for about 1.4% of Riverwater Partners LLC’s holdings, making the stock its 12th biggest position. Riverwater Partners LLC owned about 0.14% of LeMaitre Vascular worth $2,836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of LMAT. Raymond James Financial Inc. acquired a new position in shares of LeMaitre Vascular in the fourth quarter worth $14,900,000. Segall Bryant & Hamill LLC acquired a new position in LeMaitre Vascular in the 4th quarter valued at about $5,446,000. DF Dent & Co. Inc. lifted its holdings in LeMaitre Vascular by 26.2% in the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after purchasing an additional 53,797 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in LeMaitre Vascular by 45.9% in the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier’s stock valued at $13,590,000 after purchasing an additional 46,430 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $79.78 on Friday. LeMaitre Vascular, Inc. has a one year low of $62.39 and a one year high of $109.58. The company’s 50 day moving average price is $91.62 and its 200 day moving average price is $94.15. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of 43.60, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

Wall Street Analyst Weigh In

LMAT has been the topic of several recent analyst reports. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Lake Street Capital lifted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target for the company. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.25.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.